


RealRate

## PHARMACEUTICAL 2020

## Mylan II B.V. Rank 67 of 362





## PHARMACEUTICAL 2020



## Mylan II B.V. Rank 67 of 362

The relative strengths and weaknesses of Mylan II B.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Mylan II B.V. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 241% points. The greatest weakness of Mylan II B.V. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 55%, being 358% points above the market average of -303%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 6,757,300         |
| Cost of Goods Sold                          | 7,602,900         |
| Intangible Assets                           | 21,240,500        |
| Liabilities, Current                        | 5,569,100         |
| Liabilities, Non-Current                    | 12,175,100        |
| Other Assets                                | 1,108,100         |
| Other Compr. Net Income                     | -1,051,000        |
| Other Expenses                              | -21,400           |
| Other Liabilities                           | 1,627,500         |
| Other Net Income                            | 0                 |
| Property and Equipment                      | 2,149,600         |
| Research and Development                    | 639,900           |
| Revenues                                    | 11,500,500        |
| Selling, General and Administrative Expense | 2,563,600         |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 31,255,500        |
| Liabilities              | 19,371,700        |
| Expenses                 | 10,785,000        |
| Stockholders Equity      | 11,883,800        |
| Net Income               | 715,500           |
| Comprehensive Net Income | 190,000           |
| Economic Capital Ratio   | 55%               |